Alan joined Sofinnova as a Partner in 2017. He focuses on clinical-stage product companies, particularly in oncology, rare diseases and other specialty therapeutic areas. He currently serves as Chairman of Velos Biopharma Inc., Executive Chairman of Principia Biopharma, and Board member of InCarda Therapeutics Inc., XyloCor Therapeutics, and Human Longevity, Inc.
Before joining Sofinnova, Alan held executive management and board of director positions at numerous companies in the biotechnology sector. Most recently he was Executive Vice President at Celgene Corporation, and prior to that held positions of President for Celgene’s Europe, Mid-East, and Africa regions as well as Senior Vice President of Global Medical Affairs. Previously, Alan was the Chief Executive Officer at Gloucester Pharmaceuticals, Inc. until its acquisition by Celgene in 2010. Before becoming CEO at Gloucester Pharmaceuticals, he was President, Oncology for Geron Corporation and was Chief Medical Officer of Threshold Pharmaceuticals. Prior to that, Alan held numerous positions of increasing responsibility at Amgen culminating with his role as VP, Medical Affairs Europe.
Alan received an MD from Stanford University and an MPH from Harvard University. Additionally, he completed specialty training in Hematology-Oncology at the Dana Farber Cancer Institute and Brigham and Women’s Hospital. Alan has a BS in Molecular Biology from the University of Colorado.